• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6879.TWO
Share

TCI GENE Inc. Stocks

NT$ 36.45Last Updated 22.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

NT$ 29.54M

NT$ 36.45
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Fairly valued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

TCI GENE Inc., based in Taipei, Taiwan, specializes in delivering personalized preventative healthcare solutions. The company offers an extensive range of genetic screenings, including tests for nutrient metabolism, weight management, and specific G2 and ACE2 markers. Its diverse product portfolio encompasses dietary supplements, skincare items, anti-aging treatments, products designed to support children's development, and solutions targeting Alzheimer's disease. Additionally, TCI GENE provides specialized serums for DNA typing and offers professional nutrition counseling services.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, 'expensive' on EV/

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.10.2026 19:34

A merger between Tesla and SpaceX could net Musk more than $110 billion. What are the risks for shareholders?

22.10.2026 18:52

The sell-off in U.S. stocks continued: The Nasdaq fell nearly 2%. What should investors do?

22.10.2026 18:02

"Demand Is Through the Roof": Huang Identified Obstacles to Neocloud's Growth Amid Its Sell-Off

22.10.2026 17:35

Motley Fool: Six next-generation tech stocks not to forget amid the Anthropic IPO

22.10.2026 17:05

Investors seeking safe havens have driven the valuations of "toothpaste" stocks above those of the tech sector

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026